Antibiotic resistance: Counting the cost  by Spratt, Brian G.
Dispatch 1219
Antibiotic resistance: Counting the cost
Brian G. Spratt
Acquisition of drug resistance should impose a cost on
bacteria. Recent studies, however, suggest that natural
selection acts to reduce, or eliminate, the growth
disadvantage of resistant bacteria, making it difficult to
reverse the high levels of antibiotic resistance currently
found in hospitals and the community.
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Sixty years of antibiotic usage has provided an unfortunate
example of a massive experiment in microbial evolution
under intense selection. The development of antibiotics,
from the sulphonamides of the 1930s to the powerful
broad spectrum antibiotics of today, has replaced Erhlich’s
concept of the magic bullet with that of the shot gun, and
has led to a fundamental disturbance of microbial ecology.
The bacteria found within many hospitals are very differ-
ent from those of the pre-antibiotic era, as increasingly
antibiotic-resistant strains of the perennially important
pathogens have replaced their antibiotic-susceptible fore-
bears [1]. The eradication of the normal flora by powerful
antibiotics has also led to the rise in prominence of intrin-
sically antibiotic-resistant species that previously rarely
caused disease, but which can flourish when the microbial
ecology is grossly disturbed [1]. Similar problems with
antibiotic resistance are increasingly found with many of
the community-acquired pathogens.
The extent of antibiotic resistance is strongly correlated
with the level of antibiotic usage. A reduction in antibiotic
usage within hospitals and the community is frequently
urged, as it is believed that the ecological disturbance
caused by antibiotic overuse can be reversed. Antibiotic-
resistant isolates are considered to grow more slowly than
antibiotic-susceptible ones (the ‘cost’ of resistance), resis-
tant bacteria persisting only as a consequence of frequent
selection applied by antibiotic usage. Theory, however,
suggests that bacteria should adapt to eliminate the cost of
resistance, and laboratory experiments confirm this expec-
tation [2]. Acquisition of antibiotic-resistance plasmids, or
the introduction of chromosomal mutations that provide
antibiotic resistance, does initially reduce the growth rate
of bacteria [2–4]. But Bouma and Lenski [3] found that
growth of Escherichia coli containing the drug resistance
plasmid pACYC184 for 500 generations, with selection for
maintenance of the plasmid, resulted in adaptation of the
host to eliminate the cost of plasmid carriage. The most
surprising aspect of this work was that the adapted E. coli
host containing pACYC184 had a competitive advantage
over the original plasmid-free E. coli host even when grown
in the absence of antibiotic. Thus, selection for increased
fitness during long-term growth resulted in a strain that
actually grows better with pACYC184 than without.
Similarly, Schrag and Perrot [4] recently reported that
streptomycin-resistant mutants of E. coli, with either of
two different mutations in rpsL — which encodes a riboso-
mal protein — had a growth disadvantage of 14 % and
19 % per generation compared with their parent strain.
Growth of the resistant strains for 180 generations, in the
absence of streptomycin, resulted in faster growing vari-
ants that had only a slight growth disadvantage relative to
their streptomycin-susceptible parent. Contrary to expec-
tations, these variants had not reduced the cost of resis-
tance by back mutations at rpsL, but had a second site
mutation(s) that increased their growth rate, without loss
of streptomycin resistance. Having adapted to the rpsL
mutations, there was now a fitness cost of losing strepto-
mycin resistance (S.J. Schrag, V. Perrot and B.R. Levin,
personal communication). The implication is that resis-
tance to streptomycin by ribosomal alterations may ini-
tially slow growth, but secondary mutations quickly arise
that eliminate this cost, producing fitter variants in which
reversion to antibiotic-susceptibility may now be costly. 
If selection also acts to eliminate the cost of resistance in
clinical isolates, and may even produce variants in which
loss of resistance is detrimental, attempts to eliminate
resistance to an antibiotic by prohibiting the prescription
of that antibiotic will be frustrated. An important addi-
tional factor that makes it difficult to eliminate resistance
in clinical isolates is the frequent occurrence of multiply
antibiotic-resistant bacteria: restrictions on the use of one
antibiotic will have negligible effect if the other antibi-
otics to which the bacteria are resistant are still in use. A
low cost of resistance in the absence of antibiotics, but
very strong selection for resistance in the presence of
antibiotics, would be unfortunate, as an antibiotic-resistant
flora that develops after antibiotic use will take a long time
to reduce to the very low levels (close to zero) that are
required to prevent the resistant flora re-emerging when
the next course of antibiotic is prescribed. If the cost of
resistance is low, complete eradication of resistant bacteria
may only be possible if the time between courses of
antibiotics is very long (Fig. 1). 
There are few reports that directly address the cost of
resistance in natural populations, and most of the evidence
is indirect and anecdotal. However, the idea that bacteria
frequently exposed to antibiotic may adapt to eliminate
the cost of carrying a drug resistance plasmid was proposed
from studies of antibiotic resistance levels in pigs over 20
years ago, as there was no significant reduction in the per-
centage of pigs harbouring tetracycline resistance plasmids
four years after the use of tetracycline as a feed additive
was banned in the UK [5]. Rapid adaptation to the cost of
plasmid carriage also appears to have occurred in peni-
cillin-resistant isolates of Neisseria gonorrhoeae, which arose
in 1976 when a plasmid encoding the penicillin-degrading
enzyme b-lactamase entered this species. In very early iso-
lates, the plasmid was extremely unstable, and was rapidly
lost if the bacteria were grown in the absence of penicillin.
However, the plasmid was much more stable in isolates
recovered only a few months later, and is rarely lost from
current isolates, even in the absence of antibiotic selection
([6] and M. Roberts, personal communication).
A more general argument suggests that the cost of resis-
tance in clinical isolates cannot be high. Antibiotic usage
in hospitals may provide enough selection to maintain
antibiotic-resistant bacteria, even if there were a signifi-
cant cost to resistance. It is unlikely, however, that a high
cost of resistance would allow antibiotic-resistant bacteria
to compete successfully within the community where
antibiotic usage is much less than in hospitals. In many
cases antibiotic-resistant bacteria clearly do compete very
successfully in the community. For example, a high inci-
dence of antibiotic resistance has been found in the faecal
flora of individuals who have not been hospitalized or
taken antibiotics during the last three months [7]. Simi-
larly, in many countries, antibiotic resistance is common
among the oral and nasopharyngeal flora of individuals in
the community.
What can be done? Reduction in antibiotic usage is still
essential. Although this may not have much effect within
hospitals, where multiple antibiotic resistance is common
and antibiotic usage will inevitably remain high, a reduc-
tion in usage (effectively, an increase in the average inter-
val between courses of antibiotic) may decrease the extent
of resistance in the community, and should slow the
further development of resistance. New vaccines are cer-
tainly needed to prevent specific infections, but they
cannot replace antibiotics which have the potential to cure
all bacterial infections. The most pressing need is for a
number of truly novel antibiotics that have activity against
the problem pathogens, and for a policy to restrict
severely the use of new compounds to delay the develop-
ment of resistance. If this is not achieved, the golden age
of antibiotics is over.
Surprisingly, no major new class of antibiotics has been
developed for over 15 years, and several years ago some of
the major pharmaceutical companies stopped research into
novel antibacterials. This situation may be changing for
two main reasons. Firstly, the genome sequences of most
of the major bacterial pathogens will be available within a
few years, providing a plethora of potential new targets for
the design of novel antibiotics. Secondly, the Achilles heel
of current antibiotics has been that they are developed
from lead compounds, uncovered by screening for antibac-
terial activity within soil samples. For most of these
natural product antibiotics, the major problem has been
the rapid appearance of genes encoding enzymes that
inactivate them, or which protect their targets from inhibi-
tion. These antibiotic-resistance genes are believed to be
derived from genes that evolved long ago to protect the
antibiotic-producing soil microorganisms from their own
antibiotics [8]. 
This problem may now be circumvented by using combi-
natorial chemistry to provide large numbers of chemicals
to assay for activity against the novel target enzymes
arising from genome sequencing projects. In this way, it is
hoped that antibiotics will be produced for which there are
no pre-existing resistance genes. Resistance should then
develop mainly by target mutations that reduce affinity, or
by increased activity of efflux systems. The development
of resistance is inevitable, but our substantial knowledge
of the mechanisms of resistance to pre-existing antibiotics
should allow a rational choice of those bacterial targets
where resistance is likely to emerge most slowly [9].
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Figure 1
Decrease in the relative abundance of antibiotic-resistant to antibiotic-
susceptible bacteria in the absence of antibiotics, as a function of the
cost of resistance. mR and mS are the growth rates of the resistant and
susceptible bacteria, respectively; mS is set at 4.6 generations per day.
The change in the ratio of resistant to susceptible bacteria is shown for
a 1 % (blue line) and a 10 % (red line) cost of antibiotic resistance.
The time taken to reduce the abundance of resistant bacteria to some
low level is inversely related to the cost of resistance. Thus, reduction
in the initial cost of antibiotic resistance from 10 % to 1 % will increase
the time taken to eliminate resistant bacteria by a factor of ten.
(Modified with permission from [2].)
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